New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 17, 2013
22:12 EDTPFE, ZTSZoetis has good outlook but stock looks too expensive, Barron's says
Pfizer's (PFE) animal-health spin-off, Zoetis (ZTS), may be fully valued and investors should wait for a better opportunity to get in, Barron's argues. Reference Link
News For ZTS;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
November 13, 2014
09:36 EDTZTSZoetis downgraded to Neutral from Long-Term Buy at Hilliard Lyons
Subscribe for More Information
09:33 EDTZTSZoetis could get bought by Bayer for $53/share, says Jefferies
Subscribe for More Information
07:38 EDTPFEBloomberg Link to hold a conference
The Year Ahead: 2015 is being held in Washington, D.C. with a pre-conference dinner on November 13 followed by company presentations on November 14,
November 12, 2014
11:17 EDTPFELeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
10:51 EDTZTSOptions with increasing implied volatility: GNW ZTS
Subscribe for More Information
10:07 EDTZTSHigh option volume stocks: DDS FOSL ZTS CMA CLVS CZR
Subscribe for More Information
09:55 EDTZTSZoetis upgraded to Equal Weight from Underweight at Morgan Stanley
Subscribe for More Information
08:13 EDTPFEBoston Biotech to hold a conference
Subscribe for More Information
08:02 EDTPFECredit Suisse to hold a conference
Subscribe for More Information
07:15 EDTZTSSachem reports 0.9% stake in Zoetis
Sachem Head Capital Management reported a 0.9% stake in Zoetis and disclosed a letter agreement pursuant to which the Pershing Square agreed to pay Sachem an incentive fee with respect to its stake in Zoetis. Sachem agreed that for a period of time neither it nor its affiliates will trade with respect to any investment in the company.
07:13 EDTZTSZoetis takeover upside limited at current levels, says William Blair
Subscribe for More Information
07:07 EDTZTSPershing Square reports 8.5% stake in Zoetis
Subscribe for More Information
06:22 EDTZTSZoetis price target raised to $49 from $44 at Citigroup
Citigroup raised its price target for Zoetis (ZTS) shares to $49 after activist Pershing Square confirmed the accumulation of a 10% stake in the company. Citi thinks Pershing is interested in advocating for a sale of Zoetis, potentially to Valeant (VRX) if its bid for Allergan (AGN) fails. Citi believes others, including Bayer (BAYRY), could be interested in acquiring Zoetis. It keeps a Buy rating on the stock.
06:20 EDTZTSPershing Square confirms 8.5% stake in Zoetis
Subscribe for More Information
November 11, 2014
16:24 EDTZTSOn The Fly: Closing Wrap
Subscribe for More Information
15:46 EDTZTSPershing Square, Sachem Head build 10% stake in Zoetis, WSJ reports
Subscribe for More Information
15:46 EDTZTSZoetis calls active following report on activist involvement in stock
Zoetis November 40 and 42 calls are active following a report Bill Ackman's Pershing Square and Sachem Head have reportedly taken stakes in the company, according to Dow Jones. November call option implied volatility is at 37, December is at 33, January is at 31; compared to its 26-week average of 23 according to Track Data. Active call volume suggests traders taking positions for upside price movement.
15:43 EDTPFELeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
15:38 EDTZTSZoetis jumps 6% following report on activist involvement in stock
Subscribe for More Information
15:36 EDTZTSPershing, Sachem Head take activist stakes in Zoetis, DJ reports
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use